PP
ALNA

Paloma Partners’s Allena Pharmaceuticals ALNA Stock Holding History

Paloma Partners’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-17,113
Closed -$67K – 2614
2019
Q3 		$67K Sell
17,113
-34,987
-67% -$150K ﹤0.01% 1864
2019
Q2 		$212K Buy
+52,100
New +$285K ﹤0.01% 1514

Other funds holding ALNA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return

Paloma Partners's ALNA Position: Q4 2019 in Review

Paloma Partners sold out of Allena Pharmaceuticals (ALNA) in Q4 2019, closing a stake of 17,113 shares — an estimated $67K sold.

Paloma Partners first reported a position in ALNA in Q2 2019 and held it in 2 quarters. The position peaked at $212K in Q2 2019. 26 funds tracked by Wall St. Rank hold ALNA as of Q4 2019.

  • Paloma Partners reported no remaining Allena Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Paloma Partners sold 17,113 Allena Pharmaceuticals shares in Q4 2019, an estimated $67K.
  • Paloma Partners first reported a position in Allena Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Paloma Partners's Allena Pharmaceuticals position peaked at $212K in Q2 2019.
  • 26 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.